Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term PPI effects on micronutrients
IRCT20240505061656N1Phase 4Completed
- Sponsor
- Pak Emirates Military Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of omeprazole, famotidine and sucralfate in gastroesophageal reflux disease (GERD), gastritis and Zollinger–Ellison syndrome (ZES) (2 arms), sponsored by Pak Emirates Military Hospital. Primary endpoints: Changes in electrolyte levels, Changes in mineral levels and 3 more. Started Jan 2023; status: completed.
02
Drugs
omeprazolefamotidinesucralfate
03
Conditions
gastroesophageal reflux disease (GERD)gastritisZollinger–Ellison syndrome (ZES)
Beyond the preview
Go deeper on IRCT20240505061656N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240505061656N1.